Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Atezolizumab/Carboplatin/Nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in Metastatic TTF-1 Negative Lung Adenocarcinoma

NCT05689671 is registered in ClinicalTrials.gov with Nikolaj Frost MD as lead sponsor.

NCT NCT05689671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05689671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Atezolizumab/Carboplatin/Nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in Metastatic TTF-1 Negative Lung Adenocarcinoma
Lead sponsor
Nikolaj Frost MD
Phase
Phase 4
Overall status
Active, not recruiting
Start date
December 6, 2023
Completion date
October 31, 2026
Enrollment
136 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer metastatic